Cannabis
To Deal With Volatility, Consider These 3 Options on the Risk Spectrum
They range from doing nothing to jumping into the day-trading fray.
Tilray Isn't Going to Get That High
TLRY posted promising earnings, but don't expect it smoke past its current levels for long.
I Wouldn't Jump on the Tilray Bandwagon, But Here's What I Would Do
You think the Tilray brand name is worth $2.8B? Market cap is barely above $3B. Does give me pause.
I'm Treading Carefully Entering 2022 as Many Momentum Stocks Remain Bearish
Cannabis is about the only space where I'm long, and that isn't for technical reasons.
2021 Year in Review: A Very Good Market for Mega-Cap Stocks... But Not Much Else
The broader market had a very tough go of it in 2021, but you wouldn't know it unless you do some digging. From Reddit and Diamond Hands to SPACs and a stealth bear market, it's been a wild ride.
Precious Metals and Cannabis Could Surprise to the Upside in 2022
And there are a few ETFs and a silver miner that could provide the vehicles to play this hunch.
With BAD and VICE ETFs, the Devil Is in the Details
Will these exchange-traded funds pay off or send your portfolio up in a 'PUF'?
We Have Thin and Random Trading But an Upbeat Bias
We're in good shape for a continuation of the upside action next week.
Here's the Level I'm Focused on With Village Farms
Today's move has a good shot at breaking the nasty downtrend from the past three weeks.
Let's Unroll Two Cannabis-Related ETFs
Let's review Advisor Shares Pure Cannabis and Amplify Seymour Cannabis ETFs -- and what do swaps have to do with the 'sticky icky.'
2 Issues I'm Tracking in a Turkey of a Market
Uber Technologies and AdvisorShares Pure US Cannabis ETF are tempting as buys amid a landscape strewn with a lot of broken stocks.
Here's How I'm Playing This Uncertain Market Action
There's one mistake that's easy for traders to make in this sort of market.
The Easiest Way to Play the Dip in Marijuana MSOs
What caught my eye Thursday was the bullish reversal in Curaleaf Holdings and Cresco Labs during the final minutes of the trading session.
Momentum Slows as Corrective Action Intensifies
The good news is that some of the frothy speculation has cooled, and skepticism is building.
SPACs and Cannabis Are on My Screens as Traders Hunt for Action
Right now, there is tension between overbought technical conditions and an appetite for speculative trading.
Speculation Is Where It's At
Trading in cannabis, electric vehicles, and a variety of SPACs was extremely strong.
The Tide May Be Turning for Cannabis Stocks: Here's How I'm Playing It
Given that cannabis stocks have only begun to turn higher, I'm not going overly aggressive on this trade.
While Traditional Wall Street Worries, Retail Traders Stay Aggressive
Big-picture experts fret about how the indices are dancing around to inflation and other macro concerns while missing the positive action in many stocks.
I See a Direction for Compass Pathways
It may have a tough pill to swallow right now, but I'm still optimistic about psilocybin in general, and especially Cybin.
Putting Together an End-of-Year Trading Strategy
Let's review areas that are hot, those that are not, and how to position though January.
This Market Is Not Slowing Down
The opportunistic bulls are finding plenty of profitable action.
7 Ways to Invest in the Future of Cannabis
Leading advisors pick four favorite cannabis purveyors, two marijuana ETFs and one ancillary tobacco segment firm.
I See Some Magic Happening as Psilocybin Advances
New technology could take out some of the pain -- and subjectivity -- for those looking to invest in this emerging line of treatments.
For Burned Out Cannabis Investors, Here's Hit of Optimism and a Trade Idea
If you have a trader's mentality, there's a setup here worth watching.
I'm Interested in Constellation Brands, Just Not in Love
Question: Would you rather buy the beer or the stock?
This New ETF Is Totally a Wild
AdvisorShares Psychedelics ETF, which is adding Mindset Pharma and lists Cybin as a top holding, looks like a good trip.
Evergrande Fears Ease as the Market Looks Ahead to the Fed Decision
I'm looking for a continuation of strong pockets of speculative action.
A 'Trip' to the Boardroom: A Look at Psychedelic Med's Top Players
To help readers navigate this mushrooming opportunity, I've put together a list of the top corporate leaders in the field.
Here's Why I'm a Buyer of Grove Inc
GRVI caters to multiple market segments like Beauty, Pet Care, Botanical Health & Wellness, Rare Cannabinoids, and even trade shows.
Cannabis Stocks Are Lighting Up Investors' Portfolios
ETF MSOS is seen as an opportunity to get exposure to stocks that are not yet U.S. listed.